GLP-1 agonists & Eating Disorders: What to Say When Clients Ask

About this event

Are your clients asking about Ozempic, Wegovy, or other GLP-1 medications?
With the rise in popularity of GLP-1 agonists for weight loss, eating disorder practitioners are facing a growing challenge: how to ethically and effectively support clients navigating these medications; including recommendations to take these medications - especially those with active EDs, a history of EDs, or those at risk.

This webinar is for you if you:

Work with clients who have EDs, disordered eating, or weight/shape concerns
Feel unsure how to respond when clients mention GLP-1s
Are seeing these medications increasingly recommended to your clients
Want to support truly informed, values-based client decision-making
Need practical, real-world tools for conversations around risk, ethics, and autonomy

What You'll Learn

Why GLP-1 agonists present unique risks for people with eating disorders
How to talk about GLP-1 agonists
How to center consent and autonomy while educating compassionately
When (and how) these medications may be appropriate and how to support the nuance of this (How to we support clients with co morbid diabetes or PCOS who may benefit from GLP1 use a lower doses?)
How to respond to recommendations from other health professionals; including when you don't agree with them

Important Note:

This webinar will not cover the pharmacology or pathophysiology of GLP-1 agonists in detail. Instead, it focuses on relational, ethical, and client-centered responses in ED contexts.